Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Summary

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine is a clinical trial^[1].

Key Facts

• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's instance of is recorded as clinical trial^[2].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's start time is recorded as +2020-06-22T00:00:00Z^[3].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's end time is recorded as +2021-07-21T00:00:00Z^[4].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's number of participants is recorded as {'unit': '1', 'amount': '+50'}^[5].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's title is recorded as A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age^[6].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[7].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's ClinicalTrials.gov ID is recorded as NCT04445194^[8].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+59'}^[9].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's clinical trial phase is recorded as phase I clinical trial^[10].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's research site is recorded as Chongqing Medical University^[11].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's research subject recruitment status is recorded as recruiting^[12].
• Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine's study type is recorded as interventional study^[13].